Citable company snapshot
BIOGEN INC.'s latest SEC-sourced 2026-03-31 period shows $2.48B in revenue and $319.50M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:Revenues | Mar 31, 2026 | $2.48B | $2.28B | +8.7% |
| xbrl:GrossProfit | Dec 31, 2020 | $2.36B | $2.93B | -19.3% |
| xbrl:OperatingIncomeLoss | Mar 31, 2022 | $610.70M | $587.10M | +4.0% |
| xbrl:NetIncomeLoss | Mar 31, 2026 | $319.50M | $-48.90M | +753.4% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 31, 2026 | $645.50M | $511.90M | +26.1% |
| Free Cash Flow (computed) | Mar 31, 2026 | $594.30M | $468.00M | +27.0% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed Apr 29, 2026; accession 0000875045-26-000045.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
